ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma (SUMMIT-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01006252
Recruitment Status : Terminated (More possibly-related deaths on tasisulam arm; failed to pass futility hurdle)
First Posted : November 2, 2009
Last Update Posted : August 15, 2011
Sponsor:
Information provided by:
Eli Lilly and Company

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2011
  Actual Study Completion Date : March 2011
  Certification/Extension First Submitted : August 9, 2011

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 March 17, 2018
April 16, 2018
2 May 1, 2018
May 30, 2018